Contact: Kathryn Ryan, 914-740-2100, email@example.com
Risks of Fasting During Ramadan for Diabetics -- Comparing Hypoglycemia Rates with Insulin Pump versus Injections
New Rochelle, NY, April 7, 2017—A new study examining the risk of fasting during Ramadan for people with type 1 diabetes compared blood glucose control and the rates of hypoglycemia and hyperglycemia between users of insulin pump therapy versus multiple daily insulin injections. The researchers report their findings in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website.
Reem Alamoudi, MD, MHSc, Imam Abdulrahman Bin Faisal National Guard Hospital, Dammam, Saudi Arabia, and coauthors from Saudi Arabia and Qatar compared glucose data collected using self-monitoring or continuous glucose monitoring in two groups of patients, one on a regimen of daily insulin injections and the other using continuous subcutaneous insulin infusion.
In the article entitled "Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting," the researchers highlight the differences in glucose control, glucose variability, and rates of hypo- and hyper-glycemia between the two treatment groups. Hypoglycemia is common among patients with type 1 diabetes
who fast during Ramadan and is the main cause of having to break the fast.
"In the future, use of an 'artificial pancreas' hybrid closed-loop system during Ramadan may allow patients to reduce or even eliminate hypoglycemia with increased time-in-range and reduced glucose variability," says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora).
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes.
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News ), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.